Vascular Therapies announced that it closed an upsized private funding round worth more than $17 million with contributions from new and existing investors.
The Cresskill, N.J.–based clinical-stage biopharma company originally targeted $15 million for the financing, but finished with a total of $17.3 million raised.
Get the full story at our sister site, MassDevice.
Filed Under: Drug Delivery
![A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/06/51187236177_b7b566a401_k-268x170.jpg)
